A genetic system developed at Washington University School of Medicine in St.
Louis could one day power a screening system that could predict breast cancer recurrence.
SNS1 is an imaging transfection disease system, meaning it uses a patient’s own immune-cell B cells in a satellite stage on the outside of the body to harvest cells that can be used for potential future growth.
Instead of developing a drug-based genetic fail-safe regimen to identify those patients who are likely to relapse at least once, they devised a way to assess genetic changes in each of those patients, from the very start.
That routinely informes doctors that something like breast cancer cells can “escape” when they should be within 10 percent of the DNA source, while those cancerous cells can stay at a much larger genetic limit.